| Literature DB >> 31175040 |
Ariana M Garcia1, Fernando L Dias2, Antônio J Gonçalves3, Claudio R Cernea4, Emilson Q Freitas2, Marcelo B Menezes3, Marco Aurélio V Kulcsar4.
Abstract
INTRODUCTION: Supratracheal laryngectomy has been described as a surgical procedure for glottic or supraglottic cancer extending to the subglottic region and/or involving the cricoarytenoid joint, aiming to preserve laryngeal function (breathing, phonation and swallowing), without diminishing locoregional cancer control. The choice of supracricoid laryngectomy in these cases could result in a high risk of compromised resection margins.Entities:
Keywords: Laringectomia supratraqueal; Supratracheal laryngectomy; Tracheohyoido-epiglottopexy; Tracheohyoidopexy; Traqueohioidoepiglotopexia; Traqueohioidopexia
Mesh:
Year: 2019 PMID: 31175040 PMCID: PMC9422495 DOI: 10.1016/j.bjorl.2019.04.004
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Characteristics of the 29 patients submitted to STL.
| % | ||
|---|---|---|
| | ||
| | 26/29 | 89.7 |
| | 3/29 | 10.3 |
| | ||
| | 59 | – |
| | 35–82 | – |
| | ||
| | 2/29 | 6.9 |
| | 1/29 | 3.4 |
| | 1/29 | 3.4 |
STL = Supratracheal laryngectomy
2016 UICC TNM.
| TNM | pT0 | pT1 | pT2 | pT3 | pT4a |
|---|---|---|---|---|---|
| cT3 | 0 | 0 | 2 | 12 | 8 |
| cT4a | 0 | 0 | 1 | 0 | 2 |
| rT2 | 0 | 0 | 1 | 0 | 0 |
| rT3 | 1 | 0 | 0 | 2 | 0 |
UICC TNM = TNM Union Internationale Contre le Cancer Classification of Malignant Tumors
Type of surgery according to tumor location.
| Glottic region | Supraglottic region | |
|---|---|---|
| IIIa | 4 (13.8) | 0 |
| IIIa + CAU | 17 (58.6) | 0 |
| IIIb | 3 (10.3) | 2 (6.9) |
| IIIb + CAU | 3 (10.3) | 0 |
CAU = cricoarytenoid unit
Figure 1Overall, specific, disease-free and total laryngectomy-free survival at 5 years.
Acute and late postoperative complications.
| % | ||
|---|---|---|
| Neck bleeding | 3/29 | 10.3 |
| Ruptured pexy | 2/29 | 6.9 |
| Aspiration pneumonia | 1/29 | 3.4 |
| Neck cellulitis | 1/29 | 3.4 |
| Stroke | 1/29 | 3.4 |
| Total | 8/29 | 27.6 |
| Chronic aspiration | 2/29 | 6.9 |
| Neolarynx stenosis | 5/29 | 17.2 |
| Aspiration pneumonia | 1/29 | 3.4 |
| Dyspnea | 1/29 | 3.4 |
| Total | 9/29 | 31 |
Analysis by institution.
| “ISCMSP” | “INCA” | “HCFMUSP” | |
|---|---|---|---|
| 14 (48.3) | 10 (34.5) | 5 (17.2) | |
| pT0 | 0 | 1 (3.4) | 0 |
| pT1 | 0 | 0 | 0 |
| pT2 | 0 | 1 (3.4) | 3 (10.3) |
| pT3 | 7 (24.1) | 7 (24.1) | 0 |
| pT4a | 7 (24.1) | 1 (3.4) | 2 (6.9) |
| Neck bleeding | 2 (6.9) | 1 (3.4) | 0 |
| Ruptured pexy | 1 (3.4) | 0 | 1 (3.4) |
| Aspiration pneumonia | 0 | 1 (3.4) | 0 |
| Neck cellulitis | 0 | 1 (3.4) | 0 |
| Stroke | 1 (3.4) | 0 | 0 |
| Chronic aspiration | 2 (6.9) | 0 | 0 |
| Neolarynx stenosis | 5 (17.2) | 0 | 0 |
| Aspiration pneumonia | 0 | 1 (3.4) | 0 |
| Dyspnea | 0 | 1 (3.4) | 0 |
| Ruptured pexy | 1 (3.4) | 0 | 1 (3.4) |
| Local recurrence | 2 (6.9) | 1 (3.4) | 0 |
| Neck bleeding | 1 (3.4) | 0 | 0 |
| Stroke | 1 (3.4) | 0 | 0 |
| Disease recurrence | 1 (3.4) | 1 (3.4) | 0 |
| Withdrew | 11/12 (91.7) | 9/10 (90) | 5/5 (100) |
| Range of time of use (days) | 30–330 | 23/397 | 30–203 |
| Decannulated | 3/9 (33.3) | 9/9 (100) | 4/4 (100) |
| Range of time of use (days) | 47–257 | 11–90 | 60–230 |